Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. ( (JP:4882) ) just unveiled an update.
Perseus Proteomics Inc. reported its financial results for the second quarter ending September 30, 2025, showing a slight increase in net sales compared to the previous year, but still operating at a loss. The company’s financial position has weakened, with a decrease in total assets and shareholders’ equity ratio, indicating ongoing financial challenges. Despite these setbacks, the company remains committed to its strategic goals, although it has not provided a financial forecast for the fiscal year ending March 31, 2026, citing difficulty in making rational predictions.
More about Perseus Proteomics, Inc.
Perseus Proteomics Inc. is a company listed on the Tokyo Stock Exchange, specializing in proteomics, which involves the large-scale study of proteins, particularly their structures and functions. The company is focused on developing innovative solutions in the biotechnology sector, leveraging its expertise in protein research to address various market needs.
Average Trading Volume: 308,386
Technical Sentiment Signal: Sell
Current Market Cap: Yen4.59B
For a thorough assessment of 4882 stock, go to TipRanks’ Stock Analysis page.